TechFlow news, November 11 — According to The Block, Australian biopharmaceutical company Propanc Biopharma (Nasdaq: PPCB) announced it has secured up to $100 million in funding from family office Hexstone Capital.
The deal is structured through convertible preferred shares, providing Propanc with an initial investment of $1 million and up to $99 million in follow-on funding over the next year. The funds will be used to build the company's digital asset portfolio and accelerate the development of its lead oncology therapy, PRP, which is scheduled for first-in-human trials in 2026.
Add to Favorites
Share to Social Media
